

110TH CONGRESS
1ST SESSION

S. 1858

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 17, 2007

Referred to the Committee on Energy and Commerce

AN ACT

To amend the Public Health Service Act to establish grant programs to provide for education and outreach on newborn screening and coordinated followup care once newborn screening has been conducted, to reauthorize programs under part A of title XI of such Act, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
 2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Newborn Screening
 5 Saves Lives Act of 2007”.

6 **SEC. 2. IMPROVED NEWBORN AND CHILD SCREENING FOR**
 7 **HERITABLE DISORDER.**

8 Section 1109 of the Public Health Service Act (42
 9 U.S.C. 300b–8) is amended—

10 (1) by striking subsections (a), (b), and (c) and
 11 inserting the following:

12 “(a) **AUTHORIZATION OF GRANT PROGRAM.**—From
 13 amounts appropriated under subsection (j), the Secretary,
 14 acting through the Administrator of the Health Resources
 15 and Services Administration (referred to in this section
 16 as the ‘Administrator’) and in consultation with the Advi-
 17 sory Committee on Heritable Disorders in Newborns and
 18 Children (referred to in this section as the ‘Advisory Com-
 19 mittee’), shall award grants to eligible entities to enable
 20 such entities—

21 “(1) to enhance, improve or expand the ability
 22 of State and local public health agencies to provide
 23 screening, counseling, or health care services to
 24 newborns and children having or at risk for heritable
 25 disorders;

1 “(2) to assist in providing health care profes-
2 sionals and newborn screening laboratory personnel
3 with education in newborn screening and training in
4 relevant and new technologies in newborn screening
5 and congenital, genetic, and metabolic disorders;

6 “(3) to develop and deliver educational pro-
7 grams (at appropriate literacy levels) about newborn
8 screening counseling, testing, follow-up, treatment,
9 and specialty services to parents, families, and pa-
10 tient advocacy and support groups; and

11 “(4) to establish, maintain, and operate a sys-
12 tem to assess and coordinate treatment relating to
13 congenital, genetic, and metabolic disorders.

14 “(b) ELIGIBLE ENTITY.—In this section, the term
15 ‘eligible entity’ means—

16 “(1) a State or a political subdivision of a
17 State;

18 “(2) a consortium of 2 or more States or polit-
19 ical subdivisions of States;

20 “(3) a territory;

21 “(4) a health facility or program operated by or
22 pursuant to a contract with or grant from the In-
23 dian Health Service; or

1 “(5) any other entity with appropriate expertise
2 in newborn screening, as determined by the Sec-
3 retary.

4 “(c) APPROVAL FACTORS.—An application submitted
5 for a grant under subsection (a)(1) shall not be approved
6 by the Secretary unless the application contains assur-
7 ances that the eligible entity has adopted and imple-
8 mented, is in the process of adopting and implementing,
9 or will use amounts received under such grant to adopt
10 and implement the guidelines and recommendations of the
11 Advisory Committee that are adopted by the Secretary
12 and in effect at the time the grant is awarded or renewed
13 under this section, which shall include the screening of
14 each newborn for the heritable disorders recommended by
15 the Advisory Committee and adopted by the Secretary.”;

16 (2) by redesignating subsections (d) through (i)
17 as subsections (e) through (j), respectively;

18 (3) by inserting after subsection (c), the fol-
19 lowing:

20 “(d) COORDINATION.—The Secretary shall take all
21 necessary steps to coordinate programs funded with
22 grants received under this section and to coordinate with
23 existing newborn screening activities.”; and

24 (4) by striking subsection (j) (as so redesign-
25 ated) and inserting the following:

1 “(j) AUTHORIZATION OF APPROPRIATIONS.—There
2 is authorized to be appropriated—

3 “(1) to provide grants for the purpose of car-
4 rying activities under section (a)(1), \$15,000,000 for
5 fiscal year 2008; \$15,187,500 for fiscal year 2009,
6 \$15,375,000 for fiscal year 2010, \$15,562,500 for
7 fiscal year 2011, and \$15,750,000 for fiscal year
8 2012; and

9 “(2) to provide grant for the purpose of car-
10 rying out activities under paragraphs (2), (3), and
11 (4) of subsection (a), \$15,000,000 for fiscal year
12 2008, \$15,187,500 for fiscal year 2009,
13 \$15,375,000 for fiscal year 2010, \$15,562,500 for
14 fiscal year 2011, and \$15,750,000 for fiscal year
15 2012.”.

16 **SEC. 3. EVALUATING THE EFFECTIVENESS OF NEWBORN**
17 **AND CHILD SCREENING PROGRAMS.**

18 Section 1110 of the Public Health Service Act (42
19 U.S.C. 300b–9) is amended by adding at the end the fol-
20 lowing:

21 “(d) AUTHORIZATION OF APPROPRIATIONS.—There
22 are authorized to be appropriated to carry out this section
23 \$5,000,000 for fiscal year 2008, \$5,062,500 for fiscal year
24 2009, \$5,125,000 for fiscal year 2010, \$5,187,500 for fis-
25 cal year 2011, and \$5,250,000 for fiscal year 2012.”.

1 **SEC. 4. ADVISORY COMMITTEE ON HERITABLE DISORDERS**
2 **IN NEWBORNS AND CHILDREN.**

3 Section 1111 of the Public Health Service Act (42
4 U.S.C. 300b–10) is amended—

5 (1) in subsection (b)—

6 (A) by redesignating paragraph (3) as
7 paragraph (6);

8 (B) in paragraph (2), by striking “and”
9 after the semicolon;

10 (C) by inserting after paragraph (2) the
11 following:

12 “(3) make systematic evidence-based and peer-
13 reviewed recommendations that include the heritable
14 disorders that have the potential to significantly im-
15 pact public health for which all newborns should be
16 screened, including secondary conditions that may be
17 identified as a result of the laboratory methods used
18 for screening;

19 “(4) develop a model decision-matrix for new-
20 born screening expansion, including an evaluation of
21 the potential public health impact of such expansion,
22 and periodically update the recommended uniform
23 screening panel, as appropriate, based on such deci-
24 sion-matrix;

25 “(5) consider ways to ensure that all States at-
26 tain the capacity to screen for the conditions de-

scribed in paragraph (3), and include in such consideration the results of grant funding under section 1109; and”;

(D) in paragraph (6) (as so redesignated by subparagraph (A)), by striking the period at the end and inserting “, which may include recommendations, advice, or information dealing with—

“(A) follow-up activities, including those necessary to achieve rapid diagnosis in the short-term, and those that ascertain long-term case management outcomes and appropriate access to related services;

“(B) implementation, monitoring, and evaluation of newborn screening activities, including diagnosis, screening, follow-up, and treatment activities;

“(C) diagnostic and other technology used in screening;

“(D) the availability and reporting of testing for conditions for which there is no existing treatment;

“(E) conditions not included in the recommended uniform screening panel that are treatable with Food and Drug Administration-

1 approved products or other safe and effective
2 treatments, as determined by scientific evidence
3 and peer review;

4 “(F) minimum standards and related poli-
5 cies and procedures used by State newborn
6 screening programs, such as language and ter-
7 minology used by State newborn screening pro-
8 grams to include standardization of case defini-
9 tions and names of disorders for which newborn
10 screening tests are performed;

11 “(G) quality assurance, oversight, and
12 evaluation of State newborn screening pro-
13 grams, including ensuring that tests and tech-
14 nologies used by each State meet established
15 standards for detecting and reporting positive
16 screening results;

17 “(H) public and provider awareness and
18 education;

19 “(I) the cost and effectiveness of newborn
20 screening and medical evaluation systems and
21 intervention programs conducted by State-based
22 programs;

23 “(J) identification of the causes of, public
24 health impacts of, and risk factors for heritable
25 disorders; and

“(K) coordination of surveillance activities, including standardized data collection and reporting, harmonization of laboratory definitions for heritable disorders and testing results, and confirmatory testing and verification of positive results, in order to assess and enhance monitoring of newborn diseases.”; and

(2) in subsection (c)(2)—

(A) by redesignating subparagraphs (E), (F) and (G) as subparagraphs (F), (H), and (I);

(B) by inserting after subparagraph (D) the following:

“(E) the Commissioner of the Food and Drug Administration;”; and

(C) by inserting after subparagraph (F), as so redesignated, the following:

“(G) individuals with expertise in ethics and infectious diseases who have worked and published material in the area of newborn screening;”; and

(3) by adding at the end the following:

“(d) DECISION ON RECOMMENDATIONS.—

“(1) IN GENERAL.—Not later than 180 days after the Advisory Committee issues a recommenda-

1 tion pursuant to this section, the Secretary shall
2 adopt or reject such recommendation.

3 “(2) PENDING RECOMMENDATIONS.—The Sec-
4 retary shall adopt or reject any recommendation
5 issued by the Advisory Committee that is pending on
6 the date of enactment of the Newborn Screening
7 Saves Lives Act of 2007 by not later than 180 days
8 after the date of enactment of such Act.

9 “(3) DETERMINATIONS TO BE MADE PUBLIC.—
10 The Secretary shall publicize any determination on
11 adopting or rejecting a recommendation of the Advi-
12 sory Committee pursuant to this subsection, includ-
13 ing the justification for the determination.

14 “(e) ANNUAL REPORT.—Not later than 3 years after
15 the date of enactment of the Newborn Screening Saves
16 Lives Act of 2007, and each fiscal year thereafter, the Ad-
17 visory Committee shall—

18 “(1) publish a report on peer-reviewed newborn
19 screening guidelines, including follow-up and treat-
20 ment, in the United States;

21 “(2) submit such report to the appropriate com-
22 mittees of Congress, the Secretary, the Interagency
23 Coordinating Committee established under Section
24 1114, and the State departments of health; and

“(3) disseminate such report on as wide a basis
as practicable, including through posting on the
internet clearinghouse established under section
1112.

5 “(f) CONTINUATION OF OPERATION OF COM-
6 MITTEE.—Notwithstanding section 14 of the Federal Ad-
7 visory Committee Act (5 U.S.C. App.), the Advisory Com-
8 mittee shall continue to operate during the 5-year period
9 beginning on the date of enactment of the Newborn
10 Screening Saves Lives Act of 2007.

“(g) AUTHORIZATION OF APPROPRIATIONS.—There are authorized to be appropriated to carry out this section, \$1,000,000 for fiscal year 2008, \$1,012,500 for fiscal year 2009, \$1,025,000 for fiscal year 2010, \$1,037,500 for fiscal year 2011, and \$1,050,000 for fiscal year 2012.”.

16 SEC. 5. INFORMATION CLEARINGHOUSE.

Part A of title XI of the Public Health Service Act (42 U.S.C. 300b–1 et seq.) is amended by adding at the end the following:

20 "SEC. 1112. CLEARINGHOUSE OF NEWBORN SCREENING IN-
21 FORMATION.

“(a) IN GENERAL.—The Secretary, acting through the Administrator of the Health Resources and Services Administration (referred to in this part as the ‘Administrator’), in consultation with the Director of the Centers

1 for Disease Control and Prevention and the Director of
2 the National Institutes of Health, shall establish and
3 maintain a central clearinghouse of current educational
4 and family support and services information, materials, re-
5 sources, research, and data on newborn screening to—

6 “(1) enable parents and family members of
7 newborns, health professionals, industry representa-
8 tives, and other members of the public to increase
9 their awareness, knowledge, and understanding of
10 newborn screening;

11 “(2) increase awareness, knowledge, and under-
12 standing of newborn diseases and screening services
13 for expectant individuals and families; and

14 “(3) maintain current data on quality indica-
15 tors to measure performance of newborn screening,
16 such as false-positive rates and other quality indica-
17 tors as determined by the Advisory Committee under
18 section 1111.

19 “(b) INTERNET AVAILABILITY.—The Secretary, act-
20 ing through the Administrator, shall ensure that the clear-
21 inghouse described under subsection (a)—

22 “(1) is available on the Internet;

23 “(2) includes an interactive forum;

24 “(3) is updated on a regular basis, but not less
25 than quarterly; and

1 “(4) provides—

2 “(A) links to Government-sponsored, non-
3 profit, and other Internet websites of labora-
4 tories that have demonstrated expertise in new-
5 born screening that supply research-based infor-
6 mation on newborn screening tests currently
7 available throughout the United States;

8 “(B) information about newborn conditions
9 and screening services available in each State
10 from laboratories certified under subpart 2 of
11 part F of title III, including information about
12 supplemental screening that is available but not
13 required, in the State where the infant is born;

14 “(C) current research on both treatable
15 and not-yet treatable conditions for which new-
16 born screening tests are available;

17 “(D) the availability of Federal funding for
18 newborn and child screening for heritable dis-
19 orders including grants authorized under the
20 Newborn Screening Saves Lives Act of 2007;
21 and

22 “(E) other relevant information as deter-
23 mined appropriate by the Secretary.

24 “(c) NONDUPLICATION.—In developing the clearing-
25 house under this section, the Secretary shall ensure that

1 such clearinghouse minimizes duplication and supple-
 2 ments, not supplants, existing information sharing efforts.

3 “(d) AUTHORIZATION OF APPROPRIATIONS.—There
 4 are authorized to be appropriated to carry out this section,
 5 \$2,500,000 for fiscal year 2008, \$2,531,250 for fiscal year
 6 2009, \$2,562,500 for fiscal year 2010, \$2,593,750 for fis-
 7 cal year 2011, and \$2,625,000 for fiscal year 2012.”.

8 **SEC. 6. LABORATORY QUALITY AND SURVEILLANCE.**

9 Part A of title XI of the Public Health Service Act
 10 (42 U.S.C. 300b–1 et seq.), as amended by section 5, is
 11 further amended by adding at the end the following:

12 **“SEC. 1113. LABORATORY QUALITY.**

13 “(a) IN GENERAL.—The Secretary, acting through
 14 the Director of the Centers for Disease Control and Pre-
 15 vention and in consultation with the Advisory Committee
 16 on Heritable Disorders in Newborns and Children estab-
 17 lished under section 1111, shall provide for—

18 “(1) quality assurance for laboratories involved
 19 in screening newborns and children for heritable dis-
 20 orders, including quality assurance for newborn-
 21 screening tests, performance evaluation services, and
 22 technical assistance and technology transfer to new-
 23 born screening laboratories to ensure analytic valid-
 24 ity and utility of screening tests; and

1 “(2) appropriate quality control and other per-
2 formance test materials to evaluate the performance
3 of new screening tools.

4 “(b) AUTHORIZATION OF APPROPRIATIONS.—For the
5 purpose of carrying out this section, there are authorized
6 to be appropriated \$5,000,000 for fiscal year 2008,
7 \$5,062,500 for fiscal year 2009, \$5,125,000 for fiscal year
8 2010, \$5,187,500 for fiscal year 2011, and \$5,250,000
9 for fiscal year 2012.

10 **“SEC. 1114. INTERAGENCY COORDINATING COMMITTEE ON**
11 **NEWBORN AND CHILD SCREENING.**

12 “(a) PURPOSE.—It is the purpose of this section to—

13 “(1) assess existing activities and infrastruc-
14 ture, including activities on birth defects and devel-
15 opmental disabilities authorized under section 317C,
16 in order to make recommendations for programs to
17 collect, analyze, and make available data on the heri-
18 table disorders recommended by the Advisory Com-
19 mittee on Heritable Disorders in Newborns and
20 Children under section 1111, including data on the
21 incidence and prevalence of, as well as poor health
22 outcomes resulting from, such disorders; and

23 “(2) make recommendations for the establish-
24 ment of regional centers for the conduct of applied
25 epidemiological research on effective interventions to

1 promote the prevention of poor health outcomes re-
2 sulting from such disorders as well as providing in-
3 formation and education to the public on such effec-
4 tive interventions.

5 “(b) ESTABLISHMENT.—The Secretary shall estab-
6 lish an Interagency Coordinating Committee on Newborn
7 and Child Screening (referred to in this section as the
8 ‘Interagency Coordinating Committee’) to carry out the
9 purpose of this section.

10 “(c) COMPOSITION.—The Interagency Coordinating
11 Committee shall be composed of the Director of the Cen-
12 ters for Disease Control and Prevention, the Adminis-
13 trator, the Director of the Agency for Healthcare Research
14 and Quality, and the Director of the National Institutes
15 of Health, or their designees.

16 “(d) ACTIVITIES.—The Interagency Coordinating
17 Committee shall—

18 “(1) report to the Secretary and the appro-
19 priate committees of Congress on its recommenda-
20 tions related to the purpose described in subsection
21 (a); and

22 “(2) carry out other activities determined ap-
23 propriate by the Secretary.

24 “(e) AUTHORIZATION OF APPROPRIATIONS.—For the
25 purpose of carrying out this section, there are authorized

1 to be appropriated \$1,000,000 for fiscal year 2008,
 2 \$1,012,500 for fiscal year 2009, \$1,025,000 for fiscal year
 3 2010, \$1,037,500 for fiscal year 2011, and \$1,050,000
 4 for fiscal year 2012.”.

5 **SEC. 7. CONTINGENCY PLANNING.**

6 Part A of title XI of the Public Health Service Act
 7 (42 U.S.C. 300b–1 et seq.), as amended by section 6, is
 8 further amended by adding at the end the following:

9 **“SEC. 1115. NATIONAL CONTINGENCY PLAN FOR NEWBORN**
 10 **SCREENING.**

11 “(a) IN GENERAL.—Not later than 180 days after
 12 the date of enactment of this section, the Secretary, acting
 13 through the Director of the Centers for Disease Control
 14 and Prevention and in consultation with the Administrator
 15 and State departments of health (or related agencies),
 16 shall develop a national contingency plan for newborn
 17 screening for use by a State, region, or consortia of States
 18 in the event of a public health emergency.

19 “(b) CONTENTS.—The contingency plan developed
 20 under subsection (a) shall include a plan for—

21 “(1) the collection and transport of specimens;

22 “(2) the shipment of specimens to State new-
 23 born screening laboratories;

24 “(3) the processing of specimens;

1 “(4) the reporting of screening results to physi-
2 cians and families;

3 “(5) the diagnostic confirmation of positive
4 screening results;

5 “(6) ensuring the availability of treatment and
6 management resources;

7 “(7) educating families about newborn screen-
8 ing; and

9 “(8) carrying out other activities determined
10 appropriate by the Secretary.

11 **“SEC. 1116. HUNTER KELLY RESEARCH PROGRAM.**

12 “(a) NEWBORN SCREENING ACTIVITIES.—

13 “(1) IN GENERAL.—The Secretary, in conjunc-
14 tion with the Director of the National Institutes of
15 Health and taking into consideration the rec-
16 ommendations of the Advisory Committee, may con-
17 tinue carrying out, coordinating, and expanding re-
18 search in newborn screening (to be known as
19 ‘Hunter Kelly Newborn Screening Research Pro-
20 gram’) including—

21 “(A) identifying, developing, and testing
22 the most promising new screening technologies,
23 in order to improve already existing screening
24 tests, increase the specificity of newborn screen-

1 ing, and expand the number of conditions for
2 which screening tests are available;

3 “(B) experimental treatments and disease
4 management strategies for additional newborn
5 conditions, and other genetic, metabolic, hor-
6 monal and or functional conditions that can be
7 detected through newborn screening for which
8 treatment is not yet available; and

9 “(C) other activities that would improve
10 newborn screening, as identified by the Direc-
11 tor.

12 “(2) ADDITIONAL NEWBORN CONDITION.—For
13 purposes of this subsection, the term ‘additional
14 newborn condition’ means any condition that is not
15 one of the core conditions recommended by the Advi-
16 sory Committee and adopted by the Secretary.

17 “(b) FUNDING.—In carrying out the research pro-
18 gram under this section, the Secretary and the Director
19 shall ensure that entities receiving funding through the
20 program will provide assurances, as practicable, that such
21 entities will work in consultation with the appropriate
22 State departments of health, and, as practicable, focus
23 their research on screening technology not currently per-
24 formed in the States in which the entities are located, and

1 the conditions on the uniform screening panel (or the
2 standard test existing on the uniform screening panel).

3 “(c) REPORTS.—The Director is encouraged to in-
4 clude information about the activities carried out under
5 this section in the biennial report required under section
6 403 of the National Institutes of Health Reform Act of
7 2006. If such information is included, the Director shall
8 make such information available to be included on the
9 Internet Clearinghouse established under section 1112.

10 “(d) NONDUPLICATION.—In carrying out programs
11 under this section, the Secretary shall minimize duplica-
12 tion and supplement, not supplant, existing efforts of the
13 type carried out under this section.

14 “(e) PEER REVIEW.—Nothing in this section shall be
15 construed to interfere with the scientific peer-review proc-
16 ess at the National Institutes of Health.”.

Passed the Senate December 13, 2007.

Attest: NANCY ERICKSON,
Secretary.